The Influence of Haemoglobin A1c Levels on Platelet Aggregation and Platelet Turnover in Patients with Coronary Artery Disease Treated with Aspirin

نویسندگان

  • Søs Neergaard-Petersen
  • Anne-Mette Hvas
  • Erik Lerkevang Grove
  • Sanne Bøjet Larsen
  • Søren Gregersen
  • Steen Dalby Kristensen
  • Marta Letizia Hribal
چکیده

BACKGROUND Hyperglycaemia may attenuate the antiplatelet effect of aspirin and thereby increase the risk of cardiovascular events. We investigated the influence of increased haemoglobin A1c (HbA1c) levels on platelet aggregation and turnover in a large cohort of patients with coronary artery disease (CAD) with type 2 diabetes, prediabetes or no diabetes. METHODS In this observational study, we included 865 stable CAD patients on 75 mg aspirin as mono-therapy of whom 242 patients had type 2 diabetes and were receiving antidiabetic drugs. Among 623 patients without diabetes, we classified 303 patients with prediabetes (HbA1c ≥5.7-6.4% [39-47 mmol/mol]) naive to antidiabetic drugs. Platelet aggregation was evaluated by the Multiplate Analyzer using arachidonic acid and collagen and by the VerifyNow Aspirin. Platelet turnover was evaluated by immature platelets using flow cytometry and platelet activation by soluble P-selectin. RESULTS CAD patients with type 2 diabetes had higher platelet aggregation (all p-values <0.01), platelet turnover (immature platelet count, p<0.01) and platelet activation (p<0.001) than patients without diabetes. CAD patients with prediabetes had increased platelet aggregation (p = 0.02) and platelet count (p = 0.02) compared with patients without diabetes. Increased levels of HbA1c correlated positively with increased platelet aggregation using arachidonic acid (r = 0.19, p<0.0001), collagen (r = 0.10, p<0.01) and VerifyNow (r = 0.15, p<0.0001), and with platelet count (r = 0.08, p = 0.01), immature platelet count (r = 0.11, p<0.001) and soluble P-selectin (r = 0.15, p<0.0001). These associations were mainly evident in non-diabetic and prediabetic CAD patients. CONCLUSIONS CAD patients with prediabetes and diabetes may have attenuated antiplatelet effect of aspirin compared with CAD patients without diabetes. This may be related to increased platelet count in patients with prediabetes. Increased levels of HbA1c correlated positively, though weakly, with increased platelet aggregation, platelet turnover and platelet activation.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Synergic Effect of Artemisia Dracunculus (Tarragon) Extract and Aspirin (ASA) on Platelet Function

Background: Coagulation activity of platelets plays an important role in thrombosis formation, Atherosclerotic plaque establishment and cardiovascular disorders. ASA are using as an anti platelet activity drug for patients with Coronary Artery Disease (CAD). Using of plant extraction as a complementary medicine for these patients (CAD) is mostly recommended by traditional medicine specialist. ...

متن کامل

study on clopidogrel in inhibition of platelet aggregation in suspected angina patients, treated with a daily dose of 75 mg of clopidogrel for 7 days

This study was performed to assess the clopidogrel activity in inhibition of platelet aggregation in suspected angina patients on a daily dosag of 75 mg of clopidogrel for at least 7 days. This clinical trial was conducted in the outpatients department of Cardiology, Post graduate Medical Institute, Lady Reading Hospital, Peshawar from 15th October 2007 to 20th December 2007. We included 105 su...

متن کامل

study on clopidogrel in inhibition of platelet aggregation in suspected angina patients, treated with a daily dose of 75 mg of clopidogrel for 7 days

This study was performed to assess the clopidogrel activity in inhibition of platelet aggregation in suspected angina patients on a daily dosag of 75 mg of clopidogrel for at least 7 days. This clinical trial was conducted in the outpatients department of Cardiology, Post graduate Medical Institute, Lady Reading Hospital, Peshawar from 15th October 2007 to 20th December 2007. We included 105 su...

متن کامل

Is Aspirin Still the Cornerstone of Antiplatelet Therapy in Patients With Coronary Artery Disease? An Historical and Practical Narrative Review

Aspirin is an irreversible and non-selective inhibitor of cyclo-oxygenase. It represents the cornerstone of antiplatelet therapy and is used in secondary prevention of cardiovascular disease. Disagreement over the optimal maintenance dosage still exists; in America and Europe the most used doses of aspirin are 81 mg and 100 mg daily, respectively. There is also debate on the formulation and rou...

متن کامل

Genetic Determinants of On-Aspirin Platelet Reactivity: Focus on the Influence of PEAR1

BACKGROUND Platelet aggregation during aspirin treatment displays considerable inter-individual variability. A genetic etiology likely exists, but it remains unclear to what extent genetic polymorphisms determine platelet aggregation in aspirin-treated individuals. AIM To identify platelet-related single nucleotide polymorphisms (SNPs) influencing platelet aggregation during aspirin treatment...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 10  شماره 

صفحات  -

تاریخ انتشار 2015